NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:NMR - US65535H2085 - ADR
8.41 USD
+0.09 (+1.08%)
8.41 USD
0 (0%)
NMR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 238 industry peers in the Capital Markets industry. NMR has a bad profitability rating. Also its financial health evaluation is rather negative. NMR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NMR was profitable.
Each year in the past 5 years NMR has been profitable.
In multiple years NMR reported negative operating cash flow during the last 5 years.
1.2 Ratios
NMR's Return On Assets of 0.61% is on the low side compared to the rest of the industry. NMR is outperformed by 69.33% of its industry peers.
NMR has a Return On Equity of 10.62%. This is in the better half of the industry: NMR outperforms 60.08% of its industry peers.
NMR has a Return On Invested Capital of 0.66%. This is in the lower half of the industry: NMR underperforms 69.33% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NMR is significantly below the industry average of 7.00%.
The last Return On Invested Capital (0.66%) for NMR is above the 3 year average (0.42%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 10.62% | ||
| ROIC | 0.66% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
1.3 Margins
NMR has a worse Profit Margin (8.05%) than 63.45% of its industry peers.
In the last couple of years the Profit Margin of NMR has declined.
NMR has a Operating Margin of 11.60%. This is in the lower half of the industry: NMR underperforms 65.13% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
NMR has a Gross Margin (43.38%) which is in line with its industry peers.
NMR's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.6% | ||
| PM (TTM) | 8.05% | ||
| GM | 43.38% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
The number of shares outstanding for NMR has been reduced compared to 1 year ago.
NMR has less shares outstanding than it did 5 years ago.
The debt/assets ratio for NMR has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.20, we must say that NMR is in the distress zone and has some risk of bankruptcy.
NMR has a Altman-Z score of -0.20. This is in the lower half of the industry: NMR underperforms 78.15% of its industry peers.
NMR has a Debt/Equity ratio of 10.65. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 10.65, NMR is doing worse than 89.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.65 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.2 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.28 indicates that NMR may have some problems paying its short term obligations.
NMR has a worse Current ratio (0.28) than 82.35% of its industry peers.
A Quick Ratio of 0.28 indicates that NMR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.28, NMR is doing worse than 82.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.28 | ||
| Quick Ratio | 0.28 |
3. Growth
3.1 Past
NMR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.52%, which is quite impressive.
The Earnings Per Share has been growing by 10.96% on average over the past years. This is quite good.
Looking at the last year, NMR shows a decrease in Revenue. The Revenue has decreased by -2.45% in the last year.
Measured over the past years, NMR shows a quite strong growth in Revenue. The Revenue has been growing by 19.39% on average per year.
EPS 1Y (TTM)34.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-6.73%
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-8.91%
3.2 Future
NMR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.00% yearly.
The Revenue is expected to decrease by -5.88% on average over the next years.
EPS Next Y8.67%
EPS Next 2Y2.23%
EPS Next 3Y3%
EPS Next 5YN/A
Revenue Next Year-18.17%
Revenue Next 2Y-9.64%
Revenue Next 3Y-5.88%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.13, the valuation of NMR can be described as reasonable.
Based on the Price/Earnings ratio, NMR is valued a bit cheaper than the industry average as 71.85% of the companies are valued more expensively.
NMR is valuated cheaply when we compare the Price/Earnings ratio to 26.57, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 10.69, the valuation of NMR can be described as reasonable.
NMR's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NMR is cheaper than 68.91% of the companies in the same industry.
NMR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.13 | ||
| Fwd PE | 10.69 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 70.17% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.77 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.17
PEG (5Y)0.92
EPS Next 2Y2.23%
EPS Next 3Y3%
5. Dividend
5.1 Amount
NMR has a Yearly Dividend Yield of 3.91%.
NMR's Dividend Yield is comparable with the industry average which is at 6.54.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.91% |
5.2 History
On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
NMR has paid a dividend for at least 10 years, which is a reliable track record.
NMR has decreased its dividend in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
18.37% of the earnings are spent on dividend by NMR. This is a low number and sustainable payout ratio.
NMR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP18.37%
EPS Next 2Y2.23%
EPS Next 3Y3%
8.41
+0.09 (+1.08%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners42.52%
Inst Owner Change1.65%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap24.68B
Revenue(TTM)4.60T
Net Income(TTM)370.05B
Analysts73.33
Price Target8.07 (-4.04%)
Short Float %0.06%
Short Ratio2.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.91% |
Yearly Dividend0.25
Dividend Growth(5Y)15.59%
DP18.37%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.87%
Min EPS beat(2)-4.65%
Max EPS beat(2)22.4%
EPS beat(4)2
Avg EPS beat(4)16.43%
Min EPS beat(4)-10.21%
Max EPS beat(4)58.19%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.74%
PT rev (3m)-0.49%
EPS NQ rev (1m)-0.02%
EPS NQ rev (3m)1.84%
EPS NY rev (1m)1.98%
EPS NY rev (3m)9.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.53%
Revenue NY rev (3m)4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.13 | ||
| Fwd PE | 10.69 | ||
| P/S | 0.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.1 | ||
| P/tB | 1.1 | ||
| EV/EBITDA | 20.77 |
EPS(TTM)0.83
EY9.87%
EPS(NY)0.79
Fwd EY9.35%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS10.04
BVpS7.62
TBVpS7.62
PEG (NY)1.17
PEG (5Y)0.92
Graham Number11.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 10.62% | ||
| ROCE | 1.62% | ||
| ROIC | 0.66% | ||
| ROICexc | 0.74% | ||
| ROICexgc | 0.76% | ||
| OM | 11.6% | ||
| PM (TTM) | 8.05% | ||
| GM | 43.38% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexgc growth 3Y16.87%
ROICexgc growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-ScoreN/A
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.65 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 62.4 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.28 | ||
| Quick Ratio | 0.28 | ||
| Altman-Z | -0.2 |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-6.73%
EPS Next Y8.67%
EPS Next 2Y2.23%
EPS Next 3Y3%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-8.91%
Revenue Next Year-18.17%
Revenue Next 2Y-9.64%
Revenue Next 3Y-5.88%
Revenue Next 5YN/A
EBIT growth 1Y31.03%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year26775.1%
EBIT Next 3Y532.46%
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A
NOMURA HOLDINGS INC-SPON ADR / NMR FAQ
Can you provide the ChartMill fundamental rating for NOMURA HOLDINGS INC-SPON ADR?
ChartMill assigns a fundamental rating of 3 / 10 to NMR.
Can you provide the valuation status for NOMURA HOLDINGS INC-SPON ADR?
ChartMill assigns a valuation rating of 5 / 10 to NOMURA HOLDINGS INC-SPON ADR (NMR). This can be considered as Fairly Valued.
What is the profitability of NMR stock?
NOMURA HOLDINGS INC-SPON ADR (NMR) has a profitability rating of 3 / 10.
How financially healthy is NOMURA HOLDINGS INC-SPON ADR?
The financial health rating of NOMURA HOLDINGS INC-SPON ADR (NMR) is 1 / 10.
What is the expected EPS growth for NOMURA HOLDINGS INC-SPON ADR (NMR) stock?
The Earnings per Share (EPS) of NOMURA HOLDINGS INC-SPON ADR (NMR) is expected to grow by 8.67% in the next year.